NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $15.38 +0.22 (+1.45%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$18.00 +2.62 (+17.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amarin Stock (NASDAQ:AMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amarin alerts:Sign Up Key Stats Today's Range$14.90▼$15.4850-Day Range$11.29▼$17.3352-Week Range$7.08▼$17.49Volume67,795 shsAverage Volume85,721 shsMarket Capitalization$318.52 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingSell Company Overview Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. Read More Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 11% of companies evaluated by MarketBeat, and ranked 1757th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAmarin has only been the subject of 1 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.01% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amarin has recently decreased by 7.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.01% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amarin has recently decreased by 7.70%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.11 News SentimentAmarin has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Amarin this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Stock News HeadlinesWall Street Zen Upgrades Amarin (NASDAQ:AMRN) to "Buy"August 2 at 3:39 AM | americanbankingnews.comZacks Research Predicts Amarin's Q2 Earnings (NASDAQ:AMRN)August 2 at 2:25 AM | americanbankingnews.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Amarin Corporation plc (AMRN) Q2 2025 Earnings Call TranscriptJuly 30, 2025 | seekingalpha.comAmarin Reports Second Quarter 2025 Financial ResultsJuly 30, 2025 | globenewswire.comAmarin Q2 2025 Earnings PreviewJuly 29, 2025 | msn.comAMRN - Amarin Corp PLC ADR Key Metrics - MorningstarJuly 25, 2025 | morningstar.comMAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025July 23, 2025 | globenewswire.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $9.70 at the beginning of 2025. Since then, AMRN stock has increased by 58.6% and is now trading at $15.38. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) announced its earnings results on Wednesday, July, 30th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.63. The biopharmaceutical company had revenue of $72.74 million for the quarter, compared to analyst estimates of $45.45 million. Amarin had a negative trailing twelve-month return on equity of 21.18% and a negative net margin of 47.22%. Read the conference call transcript. When did Amarin's stock split? Shares of Amarin reverse split on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? Amarin subsidiaries include Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Top institutional investors of Amarin include Waterfront Wealth Inc. (0.46%), LCM Capital Management Inc (0.21%) and Bleakley Financial Group LLC (0.11%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings7/30/2025Today8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Price Target for Amarin$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-22.0%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.18 million Net Margins-47.22% Pretax Margin-44.91% Return on Equity-21.18% Return on Assets-15.00% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio2.34 Sales & Book Value Annual Sales$228.61 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value$23.62 per share Price / Book0.65Miscellaneous Outstanding Shares20,710,000Free Float20,301,000Market Cap$318.52 million OptionableOptionable Beta0.84 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AMRN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.